Regeneron CSO George Yancopoulos on AI's hype and potential
SAN FRANCISCO — Just over 20 years ago, the people of California voted to spend billions of dollars on an exciting new idea to remake medicine. Agreeing to put $3 billion toward ...
View ArticleInhibrx’s early colorectal cancer data clouded by patient death
One of Inhibrx Biosciences’ antibody candidates has shown encouraging early efficacy in colorectal cancer. But its safety is under scrutiny after a patient enrolled in the Phase 1 trial died. The...
View ArticleJ&J’s Spravato hit $1B in revenue in 2024
Johnson & Johnson’s burgeoning depression treatment Spravato eclipsed $1 billion in revenue in 2024 as the pharma’s neuroscience pipeline comes into view. In its fourth-quarter earnings on...
View ArticleShanghai Bao, Sichuan Biokin file IPOs in Hong Kong; Disc's $200M offering
Plus, news about Rivus and Crown Labs: Two Chinese biotechs file for stock listings in Hong Kong: Shanghai Bao Pharmaceuticals and Sichuan Biokin Pharmaceutical join a queue of Chinese drug developers...
View ArticleXilio reports handful of responses for combo in colorectal cancer
Xilio Therapeutics said its anti-CTLA-4 produced promising initial data in certain colorectal cancer patients enrolled in a mid-stage trial. But the drug’s future is uncertain as the company grapples...
View ArticleRFK Jr. says he’ll divest interests in CRISPR Therapeutics if confirmed for...
HHS Secretary nominee Robert F. Kennedy Jr. will divest his interests in several biopharma companies, including CRISPR Therapeutics and Dragonfly Therapeutics, if confirmed by the Senate, he said in a...
View ArticleUpdated: Biogen enacts layoffs across its research unit
Biogen is laying off staff across its research unit, marking one of the most concerted strategic decisions from Jane Grogan since she took over the department. A company spokesperson said in a...
View ArticleHealth navigation company Quantum Health lays off 4% of workforce
Longtime digital health company Quantum Health has laid off workers days after it appointed a new CEO, Endpoints News has learned. Founded in 1999, private equity-backed Quantum provides services for...
View ArticleSamsung Biologics hits revenue high, secures largest contract to date
Samsung Biologics closed 2024 on several high notes, reaching its highest annual revenue to date — and just a week ago, securing its largest client contract so far. Samsung Bio pulled in a record-high...
View ArticleChinese startup begins first clinical trial using CRISPR to edit cells...
A little-known Chinese biotech startup has zipped ahead of US companies in one of the gene editing field’s most competitive races. YolTech Therapeutics announced Monday that it started a clinical trial...
View ArticleJ&J reinforces Caplyta blockbuster projections, won't shelve neuro prospects
Johnson & Johnson made the largest splash at this year’s JP Morgan Healthcare Conference, acquiring Intra-Cellular Therapies and its neuropsychiatric drug Caplyta for $14.6 billion. On the...
View ArticleVanda loses constitutional fight over FDA's drug talks with competitors
The FDA dodged claims from Vanda Pharmaceuticals that it allegedly violated the US Constitution by recommending the same drug specifications for both Vanda and its generic competitors. The opinion,...
View ArticleAstraZeneca exec stresses Calquence's patent life ahead of next Medicare...
AstraZeneca says it plans to participate in the next round of Medicare negotiations under the Inflation Reduction Act. But this time around, the company says it’s dealing with a whole different set of...
View ArticleTeva’s MS drug and generics to add black box warning for anaphylaxis
The FDA has issued a new boxed warning for Teva Pharmaceuticals' multiple sclerosis drug Copaxone and generic versions marketed by other companies after some patients had serious allergic reactions....
View ArticleAnthos' detailed mid-stage data back its anticoagulant, but can the drug...
Anthos Therapeutics’ anticoagulant poses a lower risk of bleeding events than Bayer and J&J’s Xarelto when used to prevent blood clots in atrial fibrillation patients, full results from a mid-stage...
View ArticleBioMarin's James Sabry talks biotech M&A, dealmaking in 2025
SAN FRANCISCO — Not many biotechs survive beyond 25 years, let alone get multiple drugs approved and turn a profit. BioMarin Pharmaceutical has done all that, but finds itself navigating an unusual...
View ArticleHealth Tech startup Innovaccer lays out its acquisition strategy
Innovaccer is buying up health tech companies with the goal of providing healthcare organizations with a simple place to go for a number of tools. The Silicon Valley-based startup sells tools to...
View ArticleFDA delays decision on Stealth’s Barth syndrome drug; TargetRx raises $50M
Plus, news about Valneva and Ab&B Bio-Tech: FDA delays decision on Stealth BioTherapeutics drug to April 29: The company’s elamipretide is being developed for Barth syndrome, a rare genetic...
View ArticleAbbVie partners with Neomorph in latest molecular glue deal
Neomorph is back at it again with another pharma collaboration. The startup, which is backed by Deerfield Management and the Dana-Farber Cancer Institute, secured another partnership for its molecular...
View Article